



Share Price*

\$0.73

52-Week Range*

\$0.67-1.78

Market Cap*

\$28M

Net Revenue for 2018

\$21.9M *as of 4/25/19

Overview

Interpace Diagnostics is a fully integrated commercial and bioinformatics company that provides clinically useful molecular and related first line diagnostic tests and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. Interpace's unique molecular tests offer healthcare providers and patients the benefit of early cancer detection and prognostic evaluation and accordingly more selective surgical

and treatment options. The Company has nationwide reimbursement for its products with major healthcare providers like United Healthcare, Cigna, Medicare, Aetna, Blue Cross Blue Shield and more.

**COVERED BY 30
REGIONAL
BLUE
CROSS BLUE
SHIELD PLANS**

Thyroid Products

ThyGenX[®] /ThyGeNEXT[®] and ThyraMIR[®]

ThyGenX[®] - Thyroid Oncogene Panel

Highly specific oncogene (mutational) panel that assesses the most common genetic alternations across 8 genes associated with both papillary carcinoma and follicular carcinoma.

ThyGeNEXT[®]- Next Generation Mutation Panel

Goes above and beyond ThyGenX[®] to include numerous additional molecular markers, gene mutations, and RNA fusions. This more comprehensive set of indicators not only identifies malignant and malign nodules, but also ascertains aggressiveness and other characteristics.

ThyraMIR[®] - Thyroid miRNA Classifier

The first and only miRNA gene expression classifier and is based on the evaluation of the relative expression of 10 miRNAs.

85%
reduction in
unnecessary
surgeries

When used in combination, ThyGenX[®]/ThyGeNEXT[®] and ThyraMIR[®] offer a 94% NPV, a 74% PPV, and an 85% reduction in unnecessary surgeries. Sensitivity is 89% and Specificity is 85%

275
million lives
covered

Interpace's thyroid tests cover over 275 million lives

20K
thyroid tests
conducted

Over 20,000 molecular thyroid tests performed by over 400 physicians and hospitals nationwide



PancraGEN®

PancraGEN® is a unique, DNA-based integrated molecular pathology test that assesses the risk of pancreatic and bile duct cancer in pancreatic cysts and pancreaticobiliary solid lesions.

It is the first and only U.S. commercially available molecular test for pancreatic cancer evaluation.

55,440

estimated new cases of pancreatic cancer in 2018

80%

of surgeries reveal idolent cysts, which don't require surgery

>30,000

tests performed

PancraGEN® has better predictive value for cancer than guidelines and identifies more patients in whom surgery can be avoided

BarreGEN®

BarreGEN® enables the assessment for the risk of progression from Barrett's Esophagus, a rapidly growing condition, to esophageal cancer, allowing for more personalized management of the disease.

\$1 – \$1.5 billion
market potential in the U.S.

~3.5 million
adults in the U.S. will be diagnosed with Barrett's Esophagus

Key Accomplishments in 2018

- Launched ThyGeNEXT, our next generation thyroid panel
- Completed conversion of Rosetta Genomics and acquired equipment of out bankruptcy
- Added 30 new Blue Cross Blue Shield plants to cover thyroid assays
- Launched key opinion leaders in gastrointestinal and endocrine
- Expanded medical science liaisons in thyroid and endocrine
- Expanded PancraGEN to include biliary strictures and solid lesions

Near Term Value Drivers

- Expanding reimbursement contracts
- Building upon expansion of slide business following Rosetta transition
- Further developing BarreGEN partnership, CEP results and coverage
- Assessing pharma collaboration about next generation sequencing data
- Conducting further strategic product acquisitions
- Expanding the product line to include pancreatic juice and solid tumors along with loss of heterozygosity in thyroid
- Aiming to reach cash flow break even of \$35 million

Financials



Gross profit percentage for full year 2018 was 53%

Cash & cash equivalents on hand at 12/31/2018: \$6.1M with no long-term debt

Net Cash Used in Operating Activities was \$8.7M, as compared to \$15.3M in 2017

Reported Net Revenue of \$21.9M for 2018, an increase of 38% over 2017

Q4 2018 revenue was \$5.8M, increase of 34% over Q4 2017

Stockholder's Equity amounted to \$33M as of 12/31/18

Adjusted EBITDA was \$(4.7M) for full year 2018, as compared to \$(7.1M) in 2017

Management

Jack Stover – Chief Executive Officer
Greg Richard – Chief Commercial Officer
Syd Finkelstein, MD – Chief Scientific Officer
Alidad Mireskandari, PhD – VP of Business Development
Jim Early – Chief Financial Officer
Sara A. Jackson, PhD – VP of Clinical Development
Glenn Gershon – SVP of Operations
Christina Narick, MD – VP of Pathology

Contact

Edison Advisors
Joe Green
(646) 653-7030
jgreen@edisongroup.com